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Background: We previously reported that women from high-risk families who tested negative for a BRCA1 or BRCA2
(BRCA1/2) mutation were four times more likely to develop breast cancer compared to women in the general
population. Preventive measures and risk factors for breast cancer development in these high-risk women have not
been evaluated to the same extent as BRCA1/2 positive women. Further, there is virtually no scientific evidence
about best practices in their management and care. The proposed study will examine a role of genetic and
non-genetic factors and develop the systems and parameters for the monitoring and surveillance necessary to help
establish guidelines for the care of this high-risk population.
Methods/Design: To achieve our goals, we will assemble and follow a Canadian cohort of 1,000 cancer-free
women with a strong family history breast cancer (defined as two or more relatives affected by breast cancer under
the age of 50, or three or more relatives diagnosed with breast cancer at any age from one side of the family and
with no BRCA1/2 mutation in the family). All eligible participants will be mailed a study package including invitation
to participate, consent form, a research questionnaire to collect data regarding family history, reproductive and
lifestyle factors, as well as screening and surgery. Usual dietary intake will be assessed by a diet history questionnaire.
Biological samples including toenail clippings, urine and blood samples will be collected. These women will be
followed every two years by questionnaire to update exposure information, screening practices, surgical and
chemoprevention, and disease development.
Discussion: Findings from this study will serve to help establish clinical guidelines for the implementation of
prevention, counseling, and treatment practices for women who face an elevated risk of breast cancer due to
family history, but who do not carry a BRCA1/2 mutation.
Keywords: Family history, Breast cancer, Risk factors, Prevention, BRCA1/2 mutation, Diet, Lifestyle, Hormones,
Prospective cohort, ScreeningBackground
Approximately 10-15% of all breast cancers are estimated
to have a hereditary component [1,2] and a family history
of breast cancer is associated with an increased risk of the
disease [3]. Risk increases with the number of first-degree
relatives affected and with decreasing age at onset of the
affected family members [4]. In Canada and other coun-
tries, women with significant family history of breast and/* Correspondence: joanne.kotsopoulos@wchospital.ca
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article, unless otherwise stated.or ovarian cancer are eligible for genetic testing for muta-
tions in either one of the two breast cancer susceptibility
genes, BRCA1 and BRCA2 (BRCA1/2). Genetic screening
provides the opportunity for women identified as carriers
of a deleterious mutation to consider various risk-reducing
options (e.g., prophylactic mastectomy and/or oophorec-
tomy, tamoxifen) [5] or intensive screening (e.g., annual
MRI, mammography) [6]. Despite this, the majority of
women with a family history of breast cancer who
undergo genetic testing do not carry a BRCA1/2 mutation
[7]. This finding is often interpreted as ‘non-informative’
because the residual cancer risk is high which represents a
difficult challenge in the clinic given that there is no con-
sensus on whether high-risk women who are BRCAntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sures as women with an identified BRCA1/2 mutation.
We previously evaluated the risk of breast cancer
among 1,492 women with a strong family history of
breast cancer (i.e., two or more breast cancers under the
age of 50, or three or more breast cancers at any age),
but who tested negative for a BRCA1/2 mutation [8].
We reported a four-fold increased risk of breast cancer
among these women, equivalent to a lifetime risk of
40%. Age-specific standardized-incidence ratios (SIRs)
ranged from 14.9 in females aged 25-39 to 3.0 in females
aged 60 and over suggesting greater risks for younger
women. There was a significant excess in the number of
observed breast cancers for all subgroups of cases strati-
fied by age (65 breast cancers observed, 15 expected).
Unlike BRCA1/2 mutation carriers, no elevated risk of
ovarian cancer or any other cancer was found in these
females.
Rationale of the ‘Negative Study’
There are currently no protocols in place for the counsel-
ing of women from high-risk families without BRCA1/2
mutations. Preventive measures and risk factors for breast
cancer development have not been evaluated to the same
extent and there is currently virtually no scientific evi-
dence about best practices in their management and care.
Although risks in these women are not as high as those
for BRCA mutation carriers (40% lifetime risk compared
to 80%), they remain significantly higher than risks in the
general population (11% lifetime risk) and thus highlight
the need to improve surveillance and preventive measures
specifically for these women [9-11]. The prevention of
breast cancer in these high-risk women has a special di-
mension. First, they are not generally considered to be at
sufficiently high-risk that preventive mastectomy is war-
ranted. Second, the risk for breast cancer is site-specific,
that is, they are not at increased risk for ovarian cancer
[8,12]. Until now, the principal risk-reducing option in
high-risk women has been the use of tamoxifen or raloxi-
fene although recent findings suggest superior effective-
ness of exemestane and anastrozole in reducing the
incidence of breast cancer in high-risk postmenopausal
women [13-15]. Yearly imaging with MRI has been shown
to be a more sensitive means of screening for breast can-
cer than annual mammography for women at a high risk
of cancer due to a BRCA1 or BRCA2 mutation, or at mod-
erate risk of cancer due to a strong family history [16-19].
Despite this, our group recently found little evidence to
support the recommendation that annual MRI screening
adds benefit beyond annual mammography and ultra-
sound for the low/moderate risk population (unpublished
data). It is clear that guidelines around prophylaxis and the
appropriate use of surveillance and prevention methods are
needed. Further, a role of modifiable factors is unknown.To this end, we initiated a multi-centered, hospital-
based, cohort study of high-risk/mutation negative women
identified through genetic counseling clinics in Ontario
(‘Negative Study’) (funded by the Canadian Breast Cancer
Foundation). This study was designed to address various
research questions including: 1) what factors (including
hormonal, lifestyle factors, surgery, chemoprevention, bio-
logical markers, and mutations in other predisposing
genes) influence risk for breast cancer development; 2) to
what extent are screening or preventive measures being
utilized in this high-risk group; 3) what are the benefits of
preventive programs in reducing the incidence of breast
cancer development in this high-risk group?
Approximately 20-25% of familial breast cancers can be
attributed to a germline mutation in BRCA1 or BRCA2
[7,20]. Thus, after accounting for the known high-risk
breast cancer loci, more than 75% of the familial risk of
disease still remains unexplained [21] resulting in an
under-representation of the number of women at-risk,
and subsequently, an increase in the number of women
developing and possibly dying of cancer. Given this, there
is a need to integrate testing for germline mutations in
other known breast and ovarian cancer predisposing genes
that may collectively account for an additional 30% of the
hereditary breast cancers. Based on technological ad-
vancements with DNA sequencing technology, along with
the significant drop in the cost of sequencing, it is time to
consider a comprehensive gene panel for hereditary breast
and ovarian cancer genetic testing. This model should in-
clude testing for mutations in the 25 known Breast and
Ovarian Cancer Predisposing (i.e., BrOCaP) genes that are
involved in the balance between cell growth and cell
death, as well as maintaining genome integrity [22-36]. A
complete list of all the BrOCaP genes and their chromo-
somal location is presented in Table 1. Given their im-
portant role in breast cancer predisposition, it is timely
that genetic testing include the evaluation of mutations
in these additional 23 genes, and not only mutations in
BRCA1 and BRCA2, which represents the current test-
ing protocol in cancer genetic clinics.
Our group has developed and previously validated the
BrOCaP gene panel sequencing in our molecular genet-
ics research laboratory at the Women’s College Research
Institute for the screening of all the known BrOCaP
genes. This panel targets 411 coding exons (plus 10 bp
from the introns in each side of an exon) of 25 genes
(Table 1) in 914 amplicons. These constitute about 80 Kbp
of the human genome. We have validated the reliability of
our BrOCaP gene panel sequencing by re-identifying 91 of
the 92 previously known mutation carriers in 16 different
genes in this panel. Each of the investigated carriers in this
validation study had a different mutation including single
nucleotide changes, insertion and deletions with sizes range
from 1 to 55 bps. The only mutation that could not be
Table 1 List of genes included in the Breast and Ovarian Cancer Predisposing (BrOCaP) gene panel
Gene Chromosome Gene Chromosome Gene Chromosome
ATM chr11 MLH1 chr3 PTEN chr10
BARD1 chr2 MRE11A chr11 RAD50 chr5
BRCA1 chr17 MSH2 chr2 RAD51C chr17
BRCA2 chr13 MSH6 chr2 RAD51D chr17
BRIP1 chr17 MUTYH chr1 STK11 chr19
CDH1 chr16 NBN chr8 TP53 chr17
CHEK2 chr22 PALB2 chr16 XRCC2 chr7
EPCAM chr2 PPM1D chr17
FAM175A chr4 PMS2 chr7
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which is difficult to detect with short read sequences
(unpublished data). The prevalence and importance of
genetic variation in these additional genes has yet to be
evaluated in a large sample of women from families with
a strong family history of breast cancer. Using this panel,
we plan to evaluate the prevalence of these mutations
within our cohort.Table 2 Summary of variables to be assessed, examples and a
Variable Example
Information collected by research questionnaire
Reproductive factors Age at menarche, parity, bre
Exogenous hormonal exposures OC use, HRT use
Body size – current, at age 18, 30 and 40 Weight, height
Lifestyle factors Physical activity, smoking sta
Screening MRI, mammogram, breast b
Surgery Mastectomy, oophorectomy
Chemoprevention Tamoxifen, raloxifene, etc.
Cancer diagnosis Breast cancer, other cancers
Family history Any new cancer diagnoses
Updated contact information Participant, alternate contac
Information collected by DHQ
Queries frequency of intake over the past year
for 124 individual food items and provides
accurate estimates of usual daily dietary intake.
Linked to the Canadian Nut
database contains average v
content of 112 nutrients in
available in Canada
Information collected from medical records
Mammographic density (% density) Quantify density using Cum
MRI
Pathology for breast cancer diagnoses Histology, stage, grade, horm
treatment regimens
Information collected from biological samples
DNA Sequencing for mutations in 2
panel
Plasma Sex hormone levels, nutrien
Toenail clippings Selenium levelsBased on knowledge of the etiology of both hereditary
and sporadic breast cancer, we have a priori selected
several risk factors and biological markers which we plan
to evaluate in our study (reviewed in [37-39]). These
have been summarized in Table 2. This is not meant to
be a comprehensive list but instead an overview of po-
tentially important variables. Briefly, we will evaluate the



















ulus 4 software X
X
one-receptor status, X
3 genes in BrOCaP X X
ts X X
X X
Kotsopoulos et al. BMC Cancer 2014, 14:221 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/221parity, breastfeeding, age at first full-term pregnancy
and age at menopause, as well as a role of exogenous
hormone use including oral contraceptives (i.e., OC)
and hormone replacement therapy (i.e., HRT). The
ability to modify risk in this group of high-risk women
without a BRCA1/2 mutation through diet and lifestyle
represents a critical area of research that warrants
evaluation and has important implications for preven-
tion. Given the lack of evidence for the aforemen-
tioned risk factors in this high-risk population, this
represents a novel opportunity to establish a prevent-
ive role of modifiable risk factors. Thus, we will evalu-
ate the relationship with lifestyle factors including
body and physical activity [40,41] as well as dietary ex-
posures such as alcohol consumption [42] and folate
status [43].
Biological markers (i.e., biomarkers) of risk including
mammographic density and levels of circulating sex
hormone levels will also be assessed as these have been
shown to be important predictors of breast cancer risk
in the general population as well as other high-risk
populations [44-46]. It is of interest to investigate
whether various lifestyle factors may influence these
biomarkers and possibly breast cancer risk. We will
also evaluate the screening practices of this high-risk
group of women (e.g., mammograms, MRI, ultrasound)
as well as the use and effectiveness of chemoprevention
agents including selective estrogen receptor modula-
tors (SERMs) (e.g., tamoxifen) or aromatase inhibitors
(e.g., exemestane).Prospective recruitment: 
Family is identified by genetic counselor 
at the time of genetic test results disclosure
Proband is introduced to the study, informed which 
family members are eligible, and given 
pamphlets with WCH contact information
Interested participa
research coordinator to
and request a maile
Participant returns 1)
2) baseline research questionnaire; 3) 
4) toenail clipping sample; an
Participant provides a bl
at a local LifeLa
(blood samples are stored as frozen
Participants are followed
1) follow-up research questionnaire
Figure 1 Study design of the ‘Negative Study’.Methods/Design
Study design
The ‘Negative Study’ is a large prospective cohort study
on high risk women from BRCA1/2 mutation negative
families. A detailed study design is presented in Figure 1.
This research is study has approval from the Research
Ethics Board of each participating centre and is in compli-
ance with the Helsinki Declaration. REB approval for this
study is ongoing and was granted by Women’s College
Hospital (#2010-0027-E), Princess Margaret Hospital
(#09-0832-CE), Hamilton Health Sciences Centre (#11-632),
Lakeridge Health Centre (#2011-033), and Sunnybrook
Health Sciences Centre (#252-2012).
Study objectives
1. To determine whether the probands of the
participants in the ‘Negative Study’ carry a mutation
in any of the genes in the BrOCaP gene panel.
2. To evaluate the association between hormonal and
reproductive factors and the risk of breast cancer.
3. To evaluate the association between dietary and
lifestyle factors and the risk of breast cancer.
4. To evaluate the level of breast cancer risk reduction
with prophylactic surgery and use of selective
estrogen receptor modulators or other
chemopreventive agents (e.g., aromatase inhibitors).
5. To evaluate the extent to which screening measures
(e.g., MRI, mammography, ultrasound) are being
utilized and whether they influence breast cancer risk.Retrospective recruitment:
Family is identified by a research 
coordinator in retrospective chart review
Proband is sent an invitation letter disclosing 
which family members are eligible, with 
pamphlets and WCH contact information
nt contacts study 
 confirm eligibility 
d study package
 informed consent; 
baseline diet history questionnaire; 
d 5) medical release form
ood and urine samples 
bs laboratory 
 serum and frozen whole blood)
 every 2 years with a 
 and 2) diet history questionnaire
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biomarkers of risk (i.e., circulating sex hormone
levels, mammographic density) and the risk of breast
cancer.
Study population and eligibility
Recruitment of eligible participants
Participants are currently being recruited from the fol-
lowing cancer genetic centres in Southern Ontario:
Hamilton Regional Cancer Centre, Mt. Sinai Hospital,
Sunnybrook Health Sciences Centre, Princess Margaret
Hospital, Lakeridge Health and Women’s College Hos-
pital (WCH), the latter of which is the main research site
for this study. Recruitment at the cancer genetic centres
occurs by one of two methods: 1) prospective enrolment
in clinic or by 2) retrospective chart review (see Figure 1
for Study Design). Both methods only involve direct
contact with the proband, defined as the first woman to
make contact with the participating centre, from an eli-
gible family. Potentially eligible families are those with a
family history of breast cancer defined as three or more
breast cancers at any age, or two breast cancers diag-
nosed before the age of 50 and who do not carry a
BRCA1/2 mutation. An example of an eligible family
and relatives is displayed in Figure 2. Only a history of
invasive breast cancer is being considered in the current
study. Families are considered negative for a BRCA1/2
mutation if one female relative with breast cancer has
been confirmed by direct DNA sequencing to not be a
carrier of a mutation. Families are ineligible for the study
if any relative has tested positive for BRCA1/2 mutations.Figure 2 Pedigree/identifying eligible participants. Figure 2 displays a
women marked with * are potentially eligible for the study based on the e
relative with breast cancer, 2) have two relatives diagnosed with breast can
family (this pedigree meets both of these criteria on the maternal side) and
BRCA1/2 mutation (as marked by the negative sign).Women in families that meet the above criteria are eval-
uated for their eligibility based on the eligibility and ex-
clusion criteria outlined.
Eligibility criteria:
1. Between 25 – 65 years of age
2. Residing in Ontario, Canada
3. Have no personal history of any cancer
4. Have two or more female relatives with breast
cancer diagnosed before the age of 50 OR three
breast cancers diagnosed at any age from ONE side
of the family (maternal or paternal, not both)
5. Have at least one first degree relative with breast
cancer (i.e., mother, sister, daughter)
6. Have at least one relative with breast cancer receive
a negative result for a BRCA1/2 mutation
7. No prophylactic mastectomy at recruitment
Exclusion criteria:
1. Women from families where a BRCA1/2 mutation
has been identified after enrolment
2. Women who cannot provide a blood and urine
sample at a local laboratory
The recruitment methods are:
1. Prospective Recruitment: Eligibility of study
participation is determined at the time of genetic test
results disclosure. If the proband or one of her firstpedigree in which the woman with the arrow is the proband and the
ligibility criteria. The selected individuals all 1) have a first degree
cer before the age of 50, or three at any age from one side of the
3) have a relative with breast cancer that has tested negative for a
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the study goals, rationale and what study participation
entails is provided by the genetic counsellor. Probands
that are interested in the study are given a study
package with contact information for the research
coordinator at WCH for additional information about
the study, and are asked to contact WCH directly.
2. Retrospective Recruitment: The study coordinator
from WCH reviews pedigrees of probands that have
had genetic testing at one of the participating centres
in the past and have tested negative for a BRCA1/2
mutation. Once eligibility of the proband or her family
has been determined, the proband is sent a study
invitation letter describing the goals of the study and
whether she is or any of her relatives are eligible. If the
proband or a relative is interested in participating, she
is asked to contact WCH directly using the information
provided in the letter. All contacted probands who
have not responded to the letter after 6 months are
contacted by a research coordinator by telephone as a
follow-up.
Once an eligible participant has been enrolled in the
study, they are required to provide informed consent,
complete a baseline research and diet history question-
naires (DHQ), provide a blood, urine and toenail clip-
pings samples, and consent to a follow-up questionnaire
every two years to update exposure information and as-
certain incident diseases (Figure 1).
Data collection
i) Exposure Data Collected By Questionnaire: Data
collection by questionnaire occurs at enrolment and
every 2 years thereafter until death or completion of
a 10 year period, whichever comes first. All study
participants are mailed a consent form, a baseline
questionnaire and a DHQ at the time of enrolment.
The baseline questionnaire collects extensive
information on many potentially important exposures
and covariates, as well as family history of cancer
screening and prophylactic surgeries, and has been
used by the “Risk factor analysis for Hereditary
Breast Cancer” study which currently has over 15,000
women enrolled. Participants are also sent a DHQ
which is a food frequency questionnaire that was
developed by staff at the Risk Factor Monitoring
and Methods Branch at the National Cancer
Institute and reflects Canadian food availability
and food fortification practices [47]. The cohort is
followed biennially by questionnaire to update
exposure information and ascertain disease.
Women have the option to complete the
follow-up by mail, email, or by a telephoneinterview with a trained research assistant,
depending on their preference. Regular contact
also ensures that there is the most up to date
contact information for the participants and an
alternate contact whom we may contact in case of
loss to follow-up or death. A summary of variables,
examples of each, and the associated timeline for
collection is displayed in Table 2.
ii) Biological Specimen Collection: Participants have the
option to have their samples collected at one of
several LifeLabs locations across Ontario. All women
are encouraged to come to the centre as close to the
time of completion of the baseline questionnaire as
possible (within the first 2 years that they are
actively enrolled in the study). Briefly, two blood
samples are collected in tubes (one tube without
additives and one EDTA-containing tube) labelled
with the subject’s study number and delivered
immediately to the laboratory for processing. Serum
is collected, aliquotted and stored at -80°C. The
EDTA-containing tube is inverted several times and
stored at -80°C for future DNA extraction. An
80 mL urine sample is also collected, aliquotted and
stored at -80°C. Samples are similarly collected at
LifeLabs and are delivered to WCH every three
months on dry ice. All samples are stored in -80°C
freezers located in WCH which are alarmed and
continuously monitored. Toenail clippings are
collected at the time the baseline questionnaire is
completed and are mailed to WCH in a sealed
envelope along with the completed consent and
questionnaire at the time of enrolment.
iii) Diagnostic Information: All study participants are
asked for written permission at the time of
enrolment to review their medical records and
pathology reports to collect detailed information
on screening, treatment, and diagnoses. Once a
participant reports a cancer diagnosis during any
follow-up cycle, the hospital/clinics are sent a
requisition for the patient’s medical records.
Necessary data will be extracted from the
records by the investigator or trained study
personnel on as needed basis. Cancers can be
diagnosed through clinical means, including physical
examination, through screening (mammography,
MRI, ultrasound, CA-125) or through prophylactic
surgery. To identify cases in non-respondents who
died, we will request permission from the next of kin
to seek medical records for incident cancers.
iv) Mammographic Density: Digital mammograms
from the providing centres will be requested and
computer-assisted measurement of mammographic
density will be carried out using Cumulus 4 software
as previously described [48]. Measurements of the
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percent density will be calculated.
Laboratory analyses
i) DNA Extraction: In the WCH lab, the extracted PBL
is thawed and then processed to extract archive
quality germline DNA. Gentra Puregene DNA
extraction kits from Qiagen are used for DNA
extraction. The concentration of the extracted DNA
is measured by a Nanodrop instrument. Extracted
DNA will be stored in a lab standard 4°C refrigerator
which allows for storage of whole DNA samples in a
single tube without the need to frequently freeze and
thaw the sample which will reduce its quality
dramatically. This germline DNA sample will be used
for all genetic tests in this cohort study.
ii) BrOCaP Gene Panel Sequencing: The BrOCaP gene
panel will be tested on identified probands with
breast cancer from eligible families which will allow
identification of a larger proportion of mutation
carriers of BrOCaP genes. DNA has been collected
from these women previously at the time of their
genetic testing, and is available for research
purposes. All probands have provided written
consent for research testing of their sample. If a
proband is found to have one of the BrOCaP gene
mutations, the unaffected relative who is a part of
the ‘Negative Study’ cohort will also be tested for the
same mutation. The BrOCaP gene panel sequencing
has been developed and validated by Dr. Akbari in
our molecular genetics research laboratory at WCRI
for screening all the known BrOCaP genes (Table 1).
iii) Sex Hormone Levels: Plasma estrogen, androgen and
progesterone levels will be assayed in the laboratory
of Dr. R. Casper (Centre for Advanced Reproductive
Technology, Toronto, ON, Canada) using
radioimmunoassay kits (Vitros immunodiagnostics).
Data management
The collection, storage, updating, and retrieval of all
clinical data for the study subjects occur at the WCRI in
Toronto. Upon consent to participate, subjects are
assigned a study number which will identify their data.
Names are removed from the data, and are verified and
edited before entered into a computer file. The data are
entered into an Access Database and are secured on a
server that is only accessible to members of the centre.
Appropriate backup is regularly maintained. Cyrillic 3
software (Oxfordshire, UK) is used to update pedigrees
based on the information provided at follow-up. To pro-
tect the privacy of our participants, any files, biological
specimens, results or questionnaires with identifying
data are stored in locked cabinets for up to 15 years,after which, they will be destroyed and disposed of prop-
erly. Names are removed from biological specimens and
are identified by subject number and appropriately dis-
posed of after analysis.
Sample size
Our target enrollment is 1,000 women. Based on prelim-
inary data, we expect the incidence of breast cancer to
be 1% per year, or 10% over a 10-year period with an ex-
pected number of 250 cancers. For all power calcula-
tions, we performed 2-sided tests with α = 0.05 and
estimated the minimum detectable risk estimate at a
power of 80%. Given that exposure data for the cohort
to be evaluated in the current study is not yet available,
we utilized exposure information from our prior publica-
tions of BRCA mutation carriers. For continuous vari-
ables, we calculated the RR for extreme quantiles using
the formula by Chapman and Nam [49]. For the main
effects of parity and weight change between ages 18 and
40, we have 80% power to detect a RR of 0.55 across ex-
treme quintiles. For exposure variables that could not be
classified into quantiles (e.g., mastectomy), the exposure
was expressed as ever vs. never; we then calculated the
minimum detectable RR between the most extreme cat-
egories [50]. For the main effects of OC, HRT, and tam-
oxifen, we have 80% power to detect a RR of 1.52, 1.54,
and 0.58 comparing ever vs. never. Similarly, the RR for
coffee consumption and a mastectomy were 0.47 and
0.64, respectively.
Planned statistical analyses
Data analyses will be performed to complement specific
objectives 1 through 6 outlined above. Various exposures
which are planned to be assessed have been summarized
in Table 2. All analyses will be carried out using SAS
Version 9.1 (SAS Institute, Cary, NC, USA). For the pro-
spective cohort analyses, we will use Cox proportional
hazards models for failure-time data, using SAS PROC
PHREG, to estimate relative risks and 95% CIs associated
with the various exposures, as this allows for multivari-
ate adjustment and evaluation of interactions [51]. For
time-varying covariates, a new data record will be cre-
ated for every questionnaire cycle at which a woman is
at risk, with covariate values set at the time the ques-
tionnaire was returned. To control for confounding by
age and calendar time, we will stratify jointly by age at
start of follow-up and calendar year of the current ques-
tionnaire cycle. We will follow women without cancer
from the date of study entry (date the baseline question-
naire is completed) until either: 1) date of last completed
follow-up questionnaire; 2) a diagnosis of any cancer; 3)
death from another cause; 4) loss to follow-up; or 5)
prophylactic mastectomy. To avoid assumptions about
linearity of exposure-response relationships, we will
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tinuous variables. This reduces the chance that a small
number of extreme observations will have an undue in-
fluence on the results. We will test for trends using
quantile medians or continuous variables as appropri-
ate. To test for pairwise interactions we will calculate
interaction variables by multiplying the two risk factors
or otherwise creating appropriate categorical interaction
terms and entering them into the model. Likelihood ratio
tests will be used to calculate P-values for interaction.
Multivariate modeling will take into account both plausi-
bility of biological effects and statistical evidence of con-
founding. We will include well-established predictors of
breast cancer in multivariate modeling (unless they are in
the causal pathway). Other covariates whose biological ef-
fects or potential to confound are less certain will be ex-
amined individually in stratified analyses as applicable. We
will use a 10% change in the parameter of interest as the
criterion to select covariates into the final model [52].
Discussion
Based on our earlier findings of a significantly increased
risk of breast cancer among women from high-risk/
BRCA negative families, we initiated a prospective co-
hort study to evaluate genetic and non-genetic determi-
nants of risk and to determine the appropriate screening
and prevention practices for these women [8]. While
there are evidence-based practices for managing women
with a BRCA1/2 mutation, there is little evidence to
guide practitioners on how women from families with
breast cancer history and without BRCA1/2 mutations
should be managed [39]. Such options may include en-
hanced screening practices along with risk reduction op-
tions such as prophylactic surgery, as well as a role for
modifiable risk factors, and chemoprevention [39]. Of
critical importance is the need to determine whether
other genetic factors are involved.
In the current study, priority will be given to the inte-
gration of the comprehensive BrOCaP gene panel into
our protocol. Since recruitment is currently underway,
we are proposing to sequence the probands of the par-
ticipants for possible mutations in the additional 23
genes known to contribute to risk of breast and ovarian
cancer as a first step. Should mutations be identified,
this will allow us to offer relatives from these high-risk
families additional genetic testing, and help identify
those women who may also be at risk of developing
breast cancer due to a mutation. This will be a signifi-
cant finding for these families. Meanwhile, by collecting
information on reproductive, hormonal and lifestyle fac-
tors, as well as chemoprevention with aromatase inhibi-
tors or selective estrogen receptor modulators, we will
be in a position to evaluate a role of modifiable factors that
may lead to accurate and effective preventive interventionsspecifically for this high-risk group of women. We also
propose to address the relationship between various
purported biomarkers of breast cancer (e.g., mammo-
graphic density, sex hormone levels) and whether en-
dogenous or exogenous exposures modify any possible
relationships.
The proposed project will improve the understanding
of the biology of this disease and the mechanisms through
which risk factors may alter risk. More importantly, our
findings stand to make significant contributions to the
field of cancer prevention in high-risk/BRCA-negative
women thus having high potential to influencing public
health recommendations surrounding genetic testing,
screening and prevention. The multidisciplinary approach
of this study will allow for communication with other re-
searchers and departments to share ideas and foster col-
laborations. In addition, the interaction with many health
centers will support the translation of our research find-
ings into clinical practice.
To date, we have six centres that are actively involved
in subject recruitment and 119 women already enrolled
in the study. A major limitation to recruitment has been
the large number of ineligible pedigrees (mostly due to
lack of BRCA1/2 mutation status) or the lack of eligible
females in the family (i.e., no eligible sisters or daugh-
ters). Additional barriers to recruitment have included
the inability to contact eligible subjects directly due to
the ethical need to recruit only through the proband dir-
ectly, along with incorrect or missing contact informa-
tion for the proband. The need for research ethics board
approval at each centre has also been a constraint.
Nonetheless, by including additional centres and intro-
ducing prospective recruitment, we have been able to
enhance our participation dramatically. Strengths of the
current study include a strict definition of ‘high-risk’ and
the exclusion of families with a known BRCA mutation.
In summary, the establishment of this cohort study,
along with the wealth of epidemiological and biological
evidence to be collected, will lead to a much-needed un-
derstanding of familial breast cancer and provide evidence
to guide health professionals in the management and care
of women from high-risk/BRCA-mutation negative fam-
ilies. Ultimately, our goal is to develop viable strategies for
risk reduction. Even though genetic factors are clearly
important given these women’s familial connections to
known breast cancer patients, the potential to modify can-
cer risk in these high-risk women will also come from en-
hanced knowledge of non-genetic, modifiable factors,
including a role of dietary and lifestyle factors, as well as
chemoprevention and screening. This information will aid
in identifying preventive measures that are successful in
reducing the risk of breast cancer development and will
lead to future clinical guidelines for the management of
these high-risk women.
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